Appointments

Earlier this month, Seaport Therapeutics appointed David Wheadon MD to their board of directors.

Daphne Zohar, founder and chief executive officer at Seaport said: “It is our pleasure to welcome David Wheadon to our board of directors,”

Dr Wheadon is a pharmaceutical leader who most recently served as senior vice president, Global Regulatory Affairs, Patient Safety and Quality Assurance at AstraZeneca. He has more than three decades of experience in clinical strategy, regulatory affairs and global health policies.

While at AstraZeneca, he oversaw the global regulatory affairs, patient safety and quality assurance organisation. He also drove regulatory strategy for the development and approval of the company’s product portfolio.

Dr Wheadon is a physician and psychiatrist with more than three decades of experience in regulatory affairs.

In addition to this, he also served as a member of AstraZeneca’s Global Medicines Development Leadership team and Late-Stage Product Committee, which was responsible for the progression of AstraZeneca’s late-stage portfolio through clinical development, regulatory approva ls and market access.

“Seaport has a promising pipeline of novel antidepressants and anxiolytics, and I look forward to being a part of the journey of delivering these important new treatments to the millions of patients suffering from devastating and debilitating mental health conditions, including depression and anxiety”, commented Dr Wheadon.